Harrow, Inc. $HROW Shares Purchased by HighTower Advisors LLC

HighTower Advisors LLC increased its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 30.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,217 shares of the company’s stock after acquiring an additional 3,090 shares during the period. HighTower Advisors LLC’s holdings in Harrow were worth $352,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Harrow by 3.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company’s stock valued at $582,000 after purchasing an additional 585 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Harrow during the 4th quarter worth $25,000. MetLife Investment Management LLC raised its stake in shares of Harrow by 5.7% during the 4th quarter. MetLife Investment Management LLC now owns 18,908 shares of the company’s stock worth $634,000 after buying an additional 1,026 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Harrow by 8.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,076 shares of the company’s stock worth $640,000 after buying an additional 1,428 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock worth $55,000 after buying an additional 1,462 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on HROW shares. Cantor Fitzgerald started coverage on Harrow in a research note on Friday, July 11th. They set an “overweight” rating and a $76.00 price target for the company. William Blair started coverage on Harrow in a research note on Tuesday, June 10th. They set an “outperform” rating for the company. HC Wainwright lifted their price target on Harrow from $60.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, August 13th. Zacks Research raised Harrow from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, BTIG Research increased their price objective on Harrow from $62.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $64.67.

Harrow Stock Up 0.0%

HROW opened at $39.00 on Tuesday. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. The firm has a market cap of $1.44 billion, a P/E ratio of -156.00 and a beta of 0.33. Harrow, Inc. has a 52 week low of $20.85 and a 52 week high of $59.23. The business’s fifty day simple moving average is $34.83 and its 200 day simple moving average is $29.45.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Monday, August 11th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.23. The business had revenue of $63.74 million for the quarter, compared to analyst estimates of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.